Show simple item record

dc.contributor.authorPakdel, S
dc.contributor.authorPakdel, F
dc.contributor.authorPouralibaba, F
dc.contributor.authorKhiyavi, RK
dc.contributor.authorFalsafi, P
dc.contributor.authorEslami, H
dc.contributor.authorFakhrzadeh, V
dc.contributor.authorKahnamouii, SS
dc.date.accessioned2018-08-26T09:31:10Z
dc.date.available2018-08-26T09:31:10Z
dc.date.issued2015
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/56927
dc.description.abstractCancer stem cells (CSCs) composes a different subpopulation of tumor cells that exhibit self-renewal and tumor beginning capacity and the ability to give rise to the heterogeneous lineages of cancer cells that encompass the tumor. Since current cancer therapies fail to eliminate CSCs, ultimately leading to cancer recurrence and progression, selective targeting of CSCs with mAbs and antibody constructs reviewed here in may represent a novel and promising therapeutic strategy to eradicate cancer. CSCs have been recognized from many human tumors and share many of the characteristics of normal stem cells. Targeting CSCs could be a strategy to improve the effect of cancer therapy but this is not as simple as it seems. Targets such as CD133 could confine CSCs from normal cells enabling specific interference but indirect strategies such as interfering with the establishment of a supportive niche through anti-antigenic or anti-stoma therapy could be more effective. This review will outline the recent discoveries of mAB targeting for CSCs.
dc.language.isoEnglish
dc.relation.ispartofDer Pharmacia Lettre
dc.subject7,8 dihydro 2 [4 (trifluoromethyl)phenyl] 5h thiopyrano[4,3 d]pyrimidin 4 ol
dc.subjectacetylsalicylic acid
dc.subjectCD133 antigen
dc.subjectCD44 antibody
dc.subjectcelecoxib
dc.subjectmonoclonal antibody
dc.subjectnonsteroid antiinflammatory agent
dc.subjectprotein tyrosine kinase inhibitor
dc.subjectretinoid
dc.subjectretinol
dc.subjectsulindac
dc.subjectunclassified drug
dc.subjectArticle
dc.subjectcancer cell
dc.subjectcancer growth
dc.subjectcancer recurrence
dc.subjectcancer stem cell
dc.subjectcancer therapy
dc.subjectcarcinogenesis
dc.subjectcell lineage
dc.subjectcell renewal
dc.subjectcell subpopulation
dc.subjecteradication therapy
dc.subjecthuman
dc.subjectnonhuman
dc.subjecttarget cell
dc.subjecttumor cell
dc.titleMonoclonal antibodies as therapeutic targets in cancer stem cells
dc.typeReview
dc.citation.volume7
dc.citation.issue2
dc.citation.spage136
dc.citation.epage141
dc.citation.indexScopus


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record